GH1 and neoplasm: Previous studies have reported that GH signaling promotes tumor aggressiveness and confers resistance to multiple therapeutic modalities, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, across diverse cancer types [10,14,21,56].